Paulus Kirchhof: Anticoagulation in Patients with a Single CHADS-VA Risk Factor
Paulus Kirchhof, Professor of Cardiovascular Medicine at the University of Birmingham, Professor of Medicine (Cardiology) and Director of the Department of Cardiology at the University Medical Center Hamburg-Eppendorf, shared a post on LinkedIn about his recent article, published in NEJM, adding:
“Anticoagulation in patients with a single CHADS-VA risk factor.
SINGLE-AF is an important trial that will inform clinical decisions.
The full paper is now available at the NEJM.
Many congratulations to all who realised SINGLE AF!
You can read my thoughts on SINGLE AF and on the use of anticoagulants in patients with atrial fibrillation and a single CHADS-VA risk factor here.
What is your take on anticoagulation in patients with atrial fibrillation and a single CHADS-VA risk factor?”
Title: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke
Author: Paulus Kirchhof
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community
-
Aug 29, 2026, 15:49Ujjawal Agarwal: Alkem’s Fight Against Anemia in Rural Bihar
-
Aug 29, 2026, 15:44Christopher Cannon: Anticoagulation Shows Benefits Even in Low Risk Atrial Fibrillation Patients
-
Aug 29, 2026, 15:43Aniela Popescu: Heart Failure Care Enters a New Era With the 2026 ESC Guidelines
-
Aug 29, 2026, 15:43Isabella Presch: ASH 2026 ITP Guidelines – Beyond Platelet Counts